- Home
- VYNE
as 07-01-2025 4:00pm EST
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.
| Founded: | 2003 | Country: | United States |
| Employees: | N/A | City: | BRIDGEWATER |
| Market Cap: | 16.0M | IPO Year: | 2018 |
| Target Price: | $6.25 | AVG Volume (30 days): | 1.1M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.99 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.85 - $4.30 | Next Earning Date: | 08-13-2025 |
| Revenue: | $605,000 | Revenue Growth: | 43.03% |
| Revenue Growth (this year): | 42.51% | Revenue Growth (next year): | -35.71% |
Latest VYNE Therapeutics Inc. News
VYNE Breaking Stock News: Dive into VYNE Ticker-Specific Updates for Smart Investing
Simply Wall St.
2 months ago
VYNE Therapeutics First Quarter 2025 Earnings: Beats Expectations
GlobeNewswire
2 months ago
VYNE Therapeutics Reports 2025 First Quarter Financial Results and Provides Business Update
GlobeNewswire
2 months ago
VYNE Therapeutics Provides Update on VYN202 Program
GlobeNewswire
3 months ago
VYNE Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference
Simply Wall St.
4 months ago
VYNE Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag
GlobeNewswire
4 months ago
VYNE Therapeutics Reports 2024 Fourth Quarter and Year-End Financial Results and Provides Business Update
GlobeNewswire
4 months ago
VYNE Therapeutics to Participate in March Investor Conferences
GlobeNewswire
4 months ago
VYNE Therapeutics Initiates Phase 1b Trial of VYN202, a Novel BD2-Selective Oral BET Inhibitor, in Plaque Psoriasis
Compare VYNE vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "VYNE VYNE Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.